Transcription Factor Rational Design Improves Directed Differentiation of Human Mesenchymal Stem Cells into Skeletal Myocytes

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2011 Jan 27

PMID 21266958

Citations 21

Authors

Manuel A F V Goncalves

Josephine M Janssen

Quynh G Nguyen

Takis Athanasopoulos

Stephen D Hauschka

George Dickson

Antoine A F de Vries

Affiliations

Soon will be listed here.

Abstract

There is great interest in transdifferentiating cells from one lineage into those of another and in dedifferentiating mature cells back into a stem/progenitor cell state by deploying naturally occurring transcription factors (TFs). Often, however, steering cellular differentiation pathways in a predictable and efficient manner remains challenging. Here, we investigated the principle of combining domains from different lineage-specific TFs to improve directed cellular differentiation. As proof-of-concept, we engineered the whole-human TF MyoDCD, which has the NH(2)-terminal transcription activation domain (TAD) and adjacent DNA-binding motif of MyoD COOH-terminally fused to the TAD of myocardin (MyoCD). We found via reporter gene and marker protein assays as well as by a cell fusion readout system that, targeting the TAD of MyoCD to genes normally responsive to the skeletal muscle-specific TF MyoD enforces more robust myogenic reprogramming of nonmuscle cells than that achieved by the parental, prototypic master TF, MyoD. Human mesenchymal stem cells (hMSCs) transduced with a codon-optimized microdystrophin gene linked to a synthetic striated muscle-specific promoter and/or with MyoD or MyoDCD were evaluated for complementing the genetic defect in Duchenne muscular dystrophy (DMD) myocytes through heterotypic cell fusion. Cotransduction of hMSCs with MyoDCD and microdystrophin led to chimeric myotubes containing the highest dystrophin levels.

Citing Articles

Continuous directed evolution of a compact CjCas9 variant with broad PAM compatibility.

Schmidheini L, Mathis N, Marquart K, Rothgangl T, Kissling L, Bock D Nat Chem Biol. 2023; 20(3):333-343.

PMID: 37735239 PMC: 7616171. DOI: 10.1038/s41589-023-01427-x.

Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals?.

Gorji A, Ostaszewski P, Urbanska K, Sadkowski T Biomedicines. 2023; 11(8).

PMID: 37626825 PMC: 10452677. DOI: 10.3390/biomedicines11082329.

Efficacy and muscle safety assessment of fukutin-related protein gene therapy.

Benasutti H, Maricelli J, Seto J, Hall J, Halbert C, Wicki J Mol Ther Methods Clin Dev. 2023; 30:65-80.

PMID: 37361354 PMC: 10285450. DOI: 10.1016/j.omtm.2023.05.022.

Development and validation of a model gene therapy biodistribution assay for AVGN7 using digital droplet polymerase chain reaction.

Rodgers B, Herring S, Carias D, Chen J, Rocha A Mol Ther Methods Clin Dev. 2023; 29:494-503.

PMID: 37273901 PMC: 10236005. DOI: 10.1016/j.omtm.2023.05.007.

Single-swap editing for the correction of common Duchenne muscular dystrophy mutations.

Chai A, Chemello F, Li H, Nishiyama T, Chen K, Zhang Y Mol Ther Nucleic Acids. 2023; 32:522-535.

PMID: 37215149 PMC: 10192335. DOI: 10.1016/j.omtn.2023.04.009.

References

Dickson G, Peck D, Moore S, Barton C, Walsh F . Enhanced myogenesis in NCAM-transfected mouse myoblasts. Nature. 1990; 344(6264):348-51. DOI: 10.1038/344348a0. View

Gang E, Bosnakovski D, Simsek T, To K, Perlingeiro R . Pax3 activation promotes the differentiation of mesenchymal stem cells toward the myogenic lineage. Exp Cell Res. 2008; 314(8):1721-33. DOI: 10.1016/j.yexcr.2008.02.016. View

Morosetti R, Mirabella M, Gliubizzi C, Broccolini A, De Angelis L, Tagliafico E . MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proc Natl Acad Sci U S A. 2006; 103(45):16995-7000. PMC: 1636567. DOI: 10.1073/pnas.0603386103. View

Graf T, Enver T . Forcing cells to change lineages. Nature. 2009; 462(7273):587-94. DOI: 10.1038/nature08533. View

van Tuyn J, Pijnappels D, de Vries A, de Vries I, van der Velde-van Dijke I, Knaan-Shanzer S . Fibroblasts from human postmyocardial infarction scars acquire properties of cardiomyocytes after transduction with a recombinant myocardin gene. FASEB J. 2007; 21(12):3369-79. DOI: 10.1096/fj.07-8211com. View

Kimura E, Han J, Li S, Fall B, Ra J, Haraguchi M . Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum Mol Genet. 2008; 17(16):2507-17. PMC: 2574879. DOI: 10.1093/hmg/ddn151. View

Di Certo M, Corbi N, Strimpakos G, Onori A, Luvisetto S, Severini C . The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice. Hum Mol Genet. 2009; 19(5):752-60. DOI: 10.1093/hmg/ddp539. View

Shi D, Reinecke H, Murry C, Torok-Storb B . Myogenic fusion of human bone marrow stromal cells, but not hematopoietic cells. Blood. 2004; 104(1):290-4. DOI: 10.1182/blood-2003-03-0688. View

Horb M, Shen C, Tosh D, Slack J . Experimental conversion of liver to pancreas. Curr Biol. 2003; 13(2):105-15. DOI: 10.1016/s0960-9822(02)01434-3. View

10.

Cooper S, Kizana E, Yates J, Lo H, Yang N, Wu Z . Dystrophinopathy carrier determination and detection of protein deficiencies in muscular dystrophy using lentiviral MyoD-forced myogenesis. Neuromuscul Disord. 2007; 17(4):276-84. DOI: 10.1016/j.nmd.2006.12.010. View

11.

Lu Y, Tian C, Danialou G, Gilbert R, Petrof B, Karpati G . Targeting artificial transcription factors to the utrophin A promoter: effects on dystrophic pathology and muscle function. J Biol Chem. 2008; 283(50):34720-7. PMC: 3259868. DOI: 10.1074/jbc.M804518200. View

12.

Gregorevic P, Blankinship M, Allen J, Chamberlain J . Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther. 2008; 16(4):657-64. PMC: 2650831. DOI: 10.1038/mt.2008.28. View

13.

Goncalves M, Swildens J, Holkers M, Narain A, van Nierop G, van de Watering M . Genetic complementation of human muscle cells via directed stem cell fusion. Mol Ther. 2008; 16(4):741-8. DOI: 10.1038/mt.2008.16. View

14.

Saito T, Nakamura A, Aoki Y, Yokota T, Okada T, Osawa M . Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One. 2010; 5(8):e12239. PMC: 2923599. DOI: 10.1371/journal.pone.0012239. View

15.

Zhu B, Gulick T . Phosphorylation and alternative pre-mRNA splicing converge to regulate myocyte enhancer factor 2C activity. Mol Cell Biol. 2004; 24(18):8264-75. PMC: 515034. DOI: 10.1128/MCB.24.18.8264-8275.2004. View

16.

Darabi R, Gehlbach K, Bachoo R, Kamath S, Osawa M, Kamm K . Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat Med. 2008; 14(2):134-43. DOI: 10.1038/nm1705. View

17.

Foster H, Sharp P, Athanasopoulos T, Trollet C, Graham I, Foster K . Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther. 2008; 16(11):1825-32. DOI: 10.1038/mt.2008.186. View

18.

Salva M, Himeda C, Tai P, Nishiuchi E, Gregorevic P, Allen J . Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther. 2007; 15(2):320-9. DOI: 10.1038/sj.mt.6300027. View

19.

Yue Y, Ghosh A, Long C, Bostick B, Smith B, Kornegay J . A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther. 2008; 16(12):1944-52. PMC: 2703820. DOI: 10.1038/mt.2008.207. View

20.

Goudenege S, Pisani D, Wdziekonski B, Di Santo J, Bagnis C, Dani C . Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD. Mol Ther. 2009; 17(6):1064-72. PMC: 2835180. DOI: 10.1038/mt.2009.67. View